Meril to launch new Myval Octapro THV solution - a part of its TAVR therapy portfolio

image credit- shutterstock

India-based company, Meril, a global leader in advanced cardiovascular and structural heart solutions, is renowned for its next-generation transcatheter heart valve technologies. Meril has announced the launch of its next-generation Myval Octapro THV solution, which will be showcased at the upcoming GISE 2024 and London Valves 2024 conferences.

The Myval THV series has been a significant advancement in transcatheter aortic valve replacement (TAVR) therapy. Featuring a shorter frame size for better operator control and predictive deployment, the availability of a large size matrix including conventional, intermediate and extra-large valve diameters that allow for better sizing of the bioprosthetic valve for each patient, and supported by a large body of clinical evidence supporting the device’s daily clinical utility worldwide.

Mr. Sanjeev Bhatt, Senior Vice President, Corporate Strategy, Meril Life Sciences said, “With the launch of the Myval Octapro THV solution, physicians and patients around the world will continue to benefit from Meril’s portfolio of advanced transcatheter heart valves.”